{"id":"h-va-dual-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, erythema, swelling)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Myalgia"}]},"_chembl":{"chemblId":"CHEMBL5984914","moleculeType":null,"molecularWeight":"296.37"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a combination vaccine that stimulates immune responses against both hepatitis A and hepatitis B antigens simultaneously. By targeting two distinct hepatotropic viruses in one therapeutic regimen, it aims to improve patient compliance and provide comprehensive protection against both HAV and HBV infections.","oneSentence":"H-VA dual therapy combines hepatitis B virus (HBV) and hepatitis A virus (HAV) immunization in a single formulation to provide dual protection against both viral infections.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:22:43.827Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of hepatitis A and hepatitis B virus infections in susceptible populations"}]},"trialDetails":[{"nctId":"NCT06929962","phase":"PHASE4","title":"VA Dual Sequential Therapy","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-04-24","conditions":"Helicobacter Pylori Infection","enrollment":600},{"nctId":"NCT05649709","phase":"PHASE4","title":"Helicobacter Pylori and Vonoprazan Dual Therapy","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Nanchang University","startDate":"2023-02-13","conditions":"Helicobacter Pylori","enrollment":504},{"nctId":"NCT05719831","phase":"PHASE3","title":"Optimization of Vonoprazan--amoxicillin Dual Therapy for Eradicating Helicobacter Pyloriinfection","status":"COMPLETED","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2023-02-01","conditions":"Helicobacter Pylori Eradication Rate","enrollment":516}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["H-VA"],"phase":"marketed","status":"active","brandName":"H-VA dual therapy","genericName":"H-VA dual therapy","companyName":"The First Affiliated Hospital of Nanchang University","companyId":"the-first-affiliated-hospital-of-nanchang-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"H-VA dual therapy combines hepatitis B virus (HBV) and hepatitis A virus (HAV) immunization in a single formulation to provide dual protection against both viral infections. Used for Prevention of hepatitis A and hepatitis B virus infections in susceptible populations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}